Oklahoma City, OK
Selexys Pharmaceuticals Corporation is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases. Its lead program is an antibody (SelG1) directed against the adhesion molecule P-selectin which is currently under development in a Phase II clinical study for sickle cell disease. Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. In September 2012, Selexys completed a $25 million Series A equity financing led by MPM Capital, and entered into an agreement with Novartis Pharmaceuticals whereby Novartis was granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.